Drug Trial Radar · NCT01285323
A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma
Last checked: Nov 20, 2026Latest source record: Nov 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
464
Actual
Start
Mar 2011
Primary completion
Apr 2014
Study completion Apr 2014
Sponsor
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.Teva (TEVA)
- Sponsor type
- Industry
- First posted
- Jan 28, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to determine whether reslizumab is more effective than placebo in reducing the number of clinical asthma exacerbations (CAEs) in patients with eosinophilic asthma.
Conditions
- Eosinophilic Asthma
Interventions
ReslizumabDrug
Patients were administered intravenously over 15 to 30 minutes reslizumab at a dosage of 3.0 mg/kg at baseline and once every 4 weeks relative to baseline over 48 weeks for a total of 13 doses.
PlaceboDrug
Matching placebo (acetate sucrose buffer), administered intravenously (iv) once every 4 weeks for a total of 13 doses.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency of Clinical Asthma Exacerbations (CAEs) During 12 Months of TreatmentTime frame: Day 1 to Month 12
- Frequency of Each of the Two Criteria for Clinical Asthma Exacerbations (CAEs)Time frame: Day 1 to Month 12
Locations
104 sites in 15 countries. Site status is shown where the registry gives one.
Teva Investigational Site 48
Mobile, Alabama
Teva Investigational Site 41
Fresno, California
Teva Investigational Site 59
Long Beach, California
Teva Investigational Site 47
Denver, Colorado
Teva Investigational Site 28
Waterbury, Connecticut
Teva Investigational Site 53
Clearwater, Florida
Teva Investigational Site 27
Miami, Florida
Teva Investigational Site 25
Lawrenceville, Georgia
Teva Investigational Site 57
Metairie, Louisiana
Teva Investigational Site 46
Bangor, Maine
Teva Investigational Site 40
St Louis, Missouri
Teva Investigational Site 67
Fort Mill, South Carolina
Teva Investigational Site 44
Dallas, Texas
Teva Investigational Site 69
El Paso, Texas
Teva Investigational Site 45
San Antonio, Texas
Teva Investigational Site 121
Ciudad Autonoma de Buenos Aire, Argentina
Teva Investigational Site 126
Ciudad Autonoma de Buenos Aire, Argentina
Teva Investigational Site 123
Rosario-Santa Fe, Argentina
Teva Investigational Site 120
San Miguel de Tucuman - Tucuma, Argentina
Teva Investigational Site 150
Florianópolis, Brazil
Teva Investigational Site 140
Porto Alegre, Brazil
Teva Investigational Site 144
Porto Alegre, Brazil
Teva Investigational Site 145
Porto Alegre, Brazil
Teva Investigational Site 143
Porto Alegre, RS, Brazil
Teva Investigational Site 142
Santo André, Brazil
Teva Investigational Site 104
Newmarket, Canada
Teva Investigational Site 102
Pointe-Claire, Canada
Teva Investigational Site 105
Windsor, Canada
Teva Investigational Site 343
Grenoble, France
Teva Investigational Site 342
Marseille, France
Teva Investigational Site 341
Montpellier, France
Teva Investigational Site 360
Bad Wörishofen, Germany
Teva Investigational Site 361
Berlin, Germany
Teva Investigational Site 362
Berlin, Germany
Teva Investigational Site 366
Berlin, Germany
Teva Investigational Site 371
Bochum, Germany
Teva Investigational Site 365
Dresden, Germany
Teva Investigational Site 369
Frankfurt, Germany
Teva Investigational Site 370
Hamburg, Germany
Teva Investigational Site 372
Koblenz, Germany
Showing 40 of 104 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.